Skip to main content

CCTG Connection


Published:
Category: Publications
Publication: BRC5
BRC5 (Alliance B140503) secondary analysis publication:  Additional node dissection in the BRC5 trial was performed at the surgeon's discretion and included simple sampling, systematic sampling, or complete lymph node dissection. Researchers report the impact of the extent of lymphadenectomy on disease- and recurrence-free survival in this trial.
 
Altorki N, Damman B, Wang X, Liberman M, Wigle D, Ashrafi A, Conti M, Yasufuku K, Schuchert MJ, Stinchcombe TE.
Read More
Published:
Category: Publications
Publication: MAC20 secondary analysis
Obesity is associated with a higher risk of recurrence, mortality, comorbidities, treatment-related adverse effects, and poor quality of life in patients with breast cancer. Scalable interventions are needed to promote weight loss in this population. Can a remotely delivered weight loss intervention (WLI) reduce weight in a diverse population of women with breast cancer and a body mass index of 27 or higher? Read More
Published:
Category: Trials
Expansion of the IPROC platform study introduces a new immunotherapy combination and patient population, accelerating progress toward more effective ovarian cancer treatments

The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third substudy IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC).

Read More
Published:
Category: Trials
Trial closure: LY16

The LY16 (LYSARC RELEVANCE) phase III open-label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma trial is permanently closed.

Read More


Published:
Category: Group updates
Safety Reporting Distribution Update
On September 10, 2025 updates were made to the CCTG safety reporting distribution process. 
  • External Suspected, Unexpected, Serious Adverse Reaction (SUSAR) Distribution
  • External CCTG Safety Summary Distribution
 
Read More
Published:
Category: Group updates
CCTG is seeking a new Patient Representative

The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gastrointestinal Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gastrointestinal Disease Site Committee, the Gastrointestinal Disease Site Executive Committee, and the CCTG Patient Representative Committee.

Read More
Published:
Category: Group updates
GCP and Division 5 Training Portal Update
On September 24, 2025 the Good Clinical Practice (GCP) and Division 5 Training Portal was updated. The updates include a visual design refresh, improved navigation and conversion of modules to courses. As part of the update, a system check was added to the RIPPLE delegation log to verify that new participants have current GCP training.
Read More
Published:
Category: Publications
DYNAMIC-III Australian Study Chair and oncologist at Peter Mac, Professor Jeanne Tie
Results from the primary analysis of the ctDNA-negative cohort from the international DYNAMIC-III (CO.29) clinical trial were presented during the Presidential Symposium of the European Society for Medical Oncology Congress in Berlin, Germany and simultaneously published in Nature Magazine. The study demonstrated that a simple blood test detecting circulating tumour DNA (ctDNA) may help physicians make more personalized treatment decisions for people with advanced colon cancer. Read More